Loading
First author of METRO PLUS, the Varanasi trial that doubled survival in advanced head and neck cancer by adding cheap oral metronomic drugs to standard chemotherapy.
Akhil Kapoor is a medical oncologist at Tata Memorial Centre's Varanasi hospitals and first author of METRO PLUS (JCO Global Oncology 2026), a randomised trial of 238 patients with advanced unresectable head and neck cancer in which paclitaxel-carboplatin plus oral metronomic chemotherapy gave a median overall survival of 10 months against 5 months with chemotherapy alone (hazard ratio 0.54). His work continues the Tata Memorial tradition of trials designed for the drugs and budgets available to most of the world's patients.
Shares Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, METRO PLUS (Tata Memorial Centre, Varanasi).
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares METRO PLUS (Tata Memorial Centre, Varanasi), Tata Memorial Centre, Methotrexate, Head and neck squamous cell carcinoma.
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma.
Shares Tata Memorial Centre, Head and neck squamous cell carcinoma, Cytotoxic chemotherapy.
Shares Methotrexate, Cytotoxic chemotherapy.
Shares Methotrexate, Cytotoxic chemotherapy.
Shares Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, METRO PLUS (Tata Memorial Centre, Varanasi), Tata Memorial Centre, Methotrexate.